title: Twice-weekly dapsone-pyrimethamine for preventing PCP and cerebral toxoplasmosis.
authors.forename: B
authors.initials: B
authors.lastname: Clotet
authors.forename: G
authors.initials: G
authors.lastname: Sirera
authors.forename: J
authors.initials: J
authors.lastname: Romeu
authors.forename: J M
authors.initials: JM
authors.lastname: Gimeno
authors.forename: A
authors.initials: A
authors.lastname: Jou
authors.forename: M J
authors.initials: MJ
authors.lastname: Condom
authors.forename: J
authors.initials: J
authors.lastname: Tor
authors.forename: M
authors.initials: M
authors.lastname: Foz
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D001927:Brain Diseases / Q000150:complications / Q000517:prevention & control*; D003622:Dapsone / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications; D006801:Humans; D008297:Male; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000517:prevention & control*; D011446:Prospective Studies; D011739:Pyrimethamine / Q000008:administration & dosage / Q000627:therapeutic use*; D014123:Toxoplasmosis / Q000150:complications / Q000517:prevention & control*
chemical_list: D003622:Dapsone; D011739:Pyrimethamine